Friday, June 1, 2018

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C), with or without statin therapy, according to a study. Additionally, PCSK9 inhibitor shows comparable safety profile. 

No comments:

Post a Comment

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C),...